Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf
Go back to Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf| Gilead Sciences (NASDAQ: GILD) | Delayed: 125.83 +0.78 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.05 | 52 Week High | $108.63 | |||
| Open | $125.56 | 52 Week Low | $71.39 | |||
| Day High | $127.27 | P/E | 69.52 | |||
| Day Low | $124.98 | EPS | $1.81 | |||
| Volume | 3,353,173 | |||||
| (NYSE: MTNB) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $2.01 | |||
| Open | $0.64 | 52 Week Low | $0.41 | |||
| Day High | $0.66 | P/E | N/A | |||
| Day Low | $0.64 | EPS | $0.00 | |||
| Volume | 42,569 | |||||
